Research publications | Alfred Health

First-in-human Phase 1 open label study of the BET inhibitor ODM-207 in patients with selected solid tumours

Ameratunga M, Braña I, Bono P, Postel-Vinay S, Plummer R, Aspegren J, Korjamo T, Snapir A, de Bono JS

(2020), Brit J Cancer, 123(12), 1730-6

DOI: 10.1038/s41416-020-01077-z

The kinase polypharmacology landscape of clinical PARP inhibitors

Antolin AA, Ameratunga M, Banerji U, Clarke PA, Workman P, Al-Lazikani B

(2020), SCI REP-UK, 10(1), 2585

DOI: 10.1038/s41598-020-59074-4

Metastatic melanoma presenting as intravenous tumour thrombus

Nguyen J, Clements W, McLean C, Haydon A, Moore M, Yap KS, Mar V, Shackleton M

(2020), J MED IMAG RADIAT ON, 64(6), 814-6

DOI: 10.1111/1754-9485.13019

Case report: acute tumour lysis syndrome following encorafenib and binimetinib for v600E metastatic melanoma with large intra-abdominal mass

Byron Y, Nott L, Shackleton M

(2020), Melanoma Res, 30(6), 625-7

DOI: 10.1097/CMR.0000000000000696

Parity reduces mammary repopulating activity but does not affect mammary stem cells defined as CD24 + CD29/CD49fhi in mice

Dall GV, Vieusseux J, Seyed-Razavi Y, Godde N, Ludford-Menting M, Russell SM, Ashworth A, Anderson RL, Risbridger GP, Shackleton M, Britt KL

(2020), BREAST CANCER RES TR, 183(3), 565-75

DOI: 10.1007/s10549-020-05804-1

Feasibility and Acceptability of Fear-Less: A Stepped-Care Program to Manage Fear of Cancer Recurrence in People with Metastatic Melanoma

Lynch FA, Katona L, Jefford M, Smith AB, Shaw J, Dhillon HM, Ellen S, Phipps-Nelson J, Lai-Kwon J, Milne D, Russell L, Dax V, Diggens J, Kent H, Button-Sloan A, Elliott J, Shackleton M, Burridge H, Ftanou M

(2020), J Clin Med, 9(9), 2969

DOI: 10.3390/jcm9092969

Cancer history and risk factors in healthy older people enrolling in the ASPREE clinical trial

Orchard, Suzanne G.; Lockery, Jessica E.; Gibbs, Peter; Polekhina, Galina; Wolfe, Rory; Zalcberg, John; Haydon, Andrew; McNeil, John J.; Nelson, Mark R.; Reid, Christopher M.; Kirpach, Brenda; Murray, Anne M.; Woods, Robyn L.; ,

(2020), CONTEMP CLIN TRIALS, 96), 106095

DOI: 10.1016/j.cct.2020.106095

Towards new models of cancer care in Australia: lessons from Victoria's response to the COVID-19 pandemic

Underhill, Craig; Parente, Phillip; McArthur, Grant; Haydon, Andrew; McLachlan, Sue Anne; Wong, Zee Wan; Segelov, Eva; ,

(2020), INTERN MED J, 50(10), 1282-1285.

DOI: 10.1111/imj.15012

The Hippo pathway oncoprotein YAP promotes melanoma cell invasion and spontaneous metastasis

Zhang X, Yang L, Szeto P, Abali GK, Zhang Y, Kulkarni A, Amarasinghe K, Li J, Vergara IA, Molania R, Papenfuss AT, McLean C, Shackleton M, Harvey KF

(2020), Oncogene, 39(30), 5267-81

DOI: 10.1038/s41388-020-1362-9

Accuracy and Prognostic Significance of Oncologists’ Estimates and Scenarios for Survival Time in Advanced Gastric Cancer

Vasista, A. , Stockler, M. , Martin, A. , Pavlakis, N. , Sjoquist, K. , Goldstein, D. , Gill, S. , Jain, V. , Liu, G. , Kannourakis, G. , Kim, Y. H., Nott, L. , Snow, S. , Burge, M. , Harris, D. , Jonker, D. , Chua, Y. J., Epstein, R. , Bonaventura, A. and Kiely, B

(2019), ONCOLOGIST, 24(11), e1102-7

DOI: 10.1634/theoncologist.2018-0613

Serial circulating tumour DNA analysis during multimodality treatment of locally advanced rectal cancer: a prospective biomarker study

Tie J, Cohen JD, Wang Y, Li L, Christie M, Simons K, Elsaleh H, Kosmider S, Wong R, Yip D, Lee M, Tran B, Rangiah D, Burge M, Goldstein D, Singh M, Skinner I, Faragher I, Croxford M, Bampton C, Haydon A, Jones IT, S Karapetis C, Price T, Schaefer MJ, Ptak J, Dobbyn L, Silliman N, Kinde I, Tomasetti C, Papadopoulos N, Kinzler K, Volgestein B, Gibbs P

(2019), Gut, 68(4), 663-71

DOI: 10.1136/gutjnl-2017-315852

Towards a strategy for clinical quality registries in Australia

Ahern S, Evans S, Hopper I, Zalcberg J

(2019), Aust Health Rev, 43(3), 284-7

DOI: 10.1071/AH17201

Associations of alcohol intake, smoking, physical activity and obesity with survival following colorectal cancer diagnosis by stage, anatomic site and tumor molecular subtype

Jayasekara, H., English, D.R., Haydon, A., Hodge, A.M., Lynch, B.M., Rosty, C., Williamson, E.J., Clendenning, M., Southey, M.C., Jenkins, M.A., Room, R., Hopper, J.L., Milne, R.L., Buchanan, D.D., Giles, G.G., MacInnis, R.J.

(2018), Int J Cancer, 238-250

DOI: 10.1002/ijc.31049

The benefits of adding metformin to tamoxifen to protect the endometrium-A randomized placebo-controlled trial

Davis SR, Robinson PJ, Jane F, White S, Brown KA, Piessens S, Edwards A, McNeilage J, Woinarski J, Chipman M, Bell RJ

(2018), Clin Endocrinol, 89(5), 605-612

DOI: 10.1111/cen.13830

Surveillance imaging with FDG-PET/CT in the post-operative follow-up of stage 3 melanoma

Lewin J, Sayers L, Kee D, Walpole I, Sanelli A, Te Marvelde L, Herschtal A, Spillane J, Gyorki D, Speakman D, Estall V, Donahoe S, Pohl M, Pope K, Chua M, Sandhu S, McArthur GA, McCormack CJ, Henderson M, Hicks RJ, Shackleton M

(2018), Ann Oncol, 29(7), 1569-1574

DOI: 10.1093/annonc/mdy124

Immunotherapy induced pyrexia and the role of PET/CT

McLean L, Soon JA, Haydon A

(2018), Int J Case Rep, 2, 29

DOI: 10.28933/ijcr-2018-06-2901

Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma

Eggermont AMM, Blank CU, Mandala M, Long GV, Atkinson V, Dalle S, Haydon A, Lichinitser M, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA, Rutkowski P, Schadendorf D, Koornstra R, Hernandez-Aya L, Maio M, van den Eertwegh AJM, Grob JJ, Gutzmer R, Jamal R, Lorigan P, Ibrahim N, Marreaud S, van Akkooi ACJ, Suciu S, Robert C

(2018), N Engl J Med, 378(19), 1789-1801

DOI: 10.1056/NEJMoa1802357

Tumour mutation status and melanoma recurrence following a negative sentinel lymph node biopsy

Adler NR, Wolfe R, McArthur GA, Kelly JW, Haydon A, McLean CA, Mar VJ

(2018), Br J Cancer, 118(10), 1289-1295

DOI: 10.1038/s41416-018-0088-8

Concordance of somatic mutational profile in multiple primary melanomas

Adler NR, McLean CA, Wolfe R, Kelly JW, McArthur GA, Haydon A, Tra T, Cummings N, Mar VJ

(2018), Pigment Cell Melanoma Res, 31(5), 592-603

DOI: 10.1111/pcmr.12702

3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial

Iveson TJ, Kerr RS, Saunders MP, Cassidy J, Hollander NH, Tabernero J, Haydon A, Glimelius B, Harkin A, Allan K, McQueen J, Scudder C, Boyd KA, Briggs A, Waterston A, Medley L, Wilson C, Ellis R, Essapen S, Dhadda AS, Harrison M, Falk S, Raouf S, Rees C, Olesen RK, Propper D, Bridgewater J, Azzabi A, Farrugia D, Webb A, Cunningham D, Hickish T, Weaver A, Gollins S, Wasan HS, Paul J

(2018), Lancet Oncol, 19(4), 562-578

DOI: 10.1016/S1470-2045(18)30093-7